5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
    Meeting Abstract

    Bryce, A. H.; Alumkal, J. J.; Armstrong, A.; Higano, C. S.; Iversen, P.; Sternberg, C. N.; Rathkopf, D. E.; Loriot, Y.; de Bono, J.; Tombal, B.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs)
    Meeting Abstract

    Carles, J.; Davis, I.; De Bono, J. S.; Fizazi, K.; Gerritsen, W.; Rathkopf, D. E.; Ryan, C. J.; Saad, F.; Steuber, T.; Wilding, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Cella, D.; Escudier, B.; Tannir, N.; Powles, T.; Donskov, F.; Peltola, K.; Schmidinger, M.; Heng, D.; Mainwaring, P.; Hammers, H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from Alliance A031203 trial
    Meeting Abstract

    Choueiri, T. K.; Halabi, S.; Sanford, B.; Hahn, O.; Michaelson, M. D.; Walsh, M.; Olencki, T.; Picus, J.; Small, E. J.; Dakhil, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    Meeting Abstract

    de Wit, R.; Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A. O.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bellmunt, J.; Mullane, S. A.; Jacobus, S.; Polacek, L.; Takeda, D. Y.; Harshman, L.; Choueiri, T.; Wagle, N.; Van Allen, E. M.; Kantoff, P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • IMvigor210: Updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bellmunt, J.; Balar, A.; Galsky, M. D.; Loriot, Y.; Theodore, C.; Pulido, E. G.; Castellano, D.; Retz, M.; Niegisch, G.; Bracarda, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
    Meeting Abstract

    Beltran, H.; Danila, D.; Montgomery, B.; Szmulewitz, R.; Vaishampayan, U.; Armstrong, A.; Stein, M.; Hoimes, C.; Pinski, J.; Scher, H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
    Meeting Abstract

    Balar, A.; Bellmunt, J.; O'Donnell, P. H.; Castellano, D.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E. R.; Hahn, N. M.; de Wit, R.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save